Últimas noticias sobre GE Vernova (NYSE:GEV) Bolsa

GE VERNOVA INC

GE Vernova

GE Vernov

GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.

Double,Exposure,Image,Of,Coin,Stacks,On,Technology,Financial,Graph

Earnings

News

Pre-Market Outlook

Markets

STLD

TSLA

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: PM, STLD, GEV, TSLA y T.

5 acciones en el foco este miércoles: PM, STLD, GEV, TSLA y T

GE Vernova Inc

GENERAL ENTERPRISE VENTUR by GENERAL ENTERPRISE VENTURES INC.

General Enterprise Ventures Inc

Gevo Inc

Strategic agreement brings innovative electrotherapy and orthotic solutions to America's veterans, active duty and DoD personnel
ALEXANDRIA, Va., June 24, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455131-1&amp;h=3455018313&amp;u=https%3A%2F%2Fwww.mellingmedical.com%2F&amp;a=Melling">Melling</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455131-1&amp;h=282231282&amp;u=https%3A%2F%2Fwww.mellingmedical.com%2F&amp;a=Medical">Medical</a>&nbsp;announced today a new strategic relationship with Zynex Medical, an industry pioneer in non-invasive medical devices for pain management and rehabilitation. The collaboration leverages MellingMedical's status as an SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to bring Zynex's innovative pain management solutions to federal healthcare providers serving America's military personnel, DoD and veterans.

Biotech

General

ZYXI

MellingMedical Teams Up With Zynex Medical To Expand Access To Non-Invasive Pain Management Solutions Across Federal Healthcare System

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $16 price target.

Price Target

Analyst Ratings

BMEA

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target

NXXT

NextNRG 2025 Revenue $6.6M, Up 148% YoY

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile
Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025
SYDNEY and BUNDOORA, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the signing of a supply agreement with Cyclotek to radiolabel RAD 402 with Terbium-161 (161Tb) in Australia, which supports the initiation of a Phase 1 clinical trial. RAD 402 is an anti-Kallikrein Related Peptidase 3 (KLK3) monoclonal antibody radiotherapeutic labelled with the radionuclide 161Tb for treatment of prostate cancer.
RAD 402 has been designed to target KLK3, which is highly expressed in the prostate, with very limited/no expression in other tissues and organs. Compared to 177Lu, 161Tb emits additional Auger and conversion electrons alongside its β-radiation, which can lead to potentially improved antitumoral therapeutic efficacy. 161Tb-RAD 402 is the first company-sponsored Phase I trial in prostate cancer using 161Tb.
Under the agreement, Cyclotek will produce and provide doses of 161Tb-labeled RAD 402 to support Radiopharm's upcoming Phase 1 clinical trial in prostate cancer in Australia. The Phase 1 trial is anticipated to start in the second half of 2025.

RADX

Radiopharm Theranostics Signs Supply Agreement With Cyclotek To Radiolabel RAD 402 With Terbium-161 In Australia, Which Supports Initiation Of Phase 1 Clinical Trial

NAOV

NanoVibronix Announces A Regional Hospital Signed Agreement to Acquire Two ENvue Navigation Systems

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) with a Buy and maintains $30 price target.

CERO

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

As markets hold steady despite rising geopolitical tensions, top strategists are urging caution that ignoring key risks may expose investors to short-term shocks and a potentially deeper market correction.
What Happened: Lori Calvasina,&nbsp;head of U.S. equity strategy&nbsp;at&nbsp;RBC Capital Markets,&nbsp;&nbsp;identified three major risks that could influence the future of stocks. These encompass potential valuation compression due to escalating national security concerns, a potential derailment of sentiment recovery following April&#8217;s brief bear market, and the possible impact of fluctuating oil prices on U.S. equities.
Despite these looming risks, stocks experienced a rally on Monday, following Iran&#8217;s performative retaliation, which led to a 7% drop in oil prices, thereby boosting investor optimism. However, David Bahnsen, chief investment officer with The Bahnsen Group, warns that with markets already priced for &#8220;multiple best-case scenarios,&#8221; there remains &#8220;plenty of risk for short-term volatility.&#8221;
Meanwhile, JPMorgan strategist David Kelly advises investors to focus on known risks, such as tariffs potentially fueling inflation and keeping interest rates high, even as the threat of war remains uncertain.
Overall, economists encourage investors to concentrate on the &#8220;known&#8221; unknowns—like the possibility of tariffs pushing inflation higher and sustaining elevated interest rates. Ignoring geopolitical risks may not signal optimism but could instead point to a more significant downturn ahead.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/23/06/33000234/california-democrat-ro-khanna-questions-feds-2-inflation-target-why-is-it-sacrosanct-as-opposed-to-s" target="_blank" rel="noreferrer noopener">Ro Khanna Wants To Know Why Fed's 2% Inflation Target Is &#8216;Sacrosanct&#8217; &#8211; Benzinga</a>
Why It Matters: The recent Israel-Iran airstrikes <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45943707/us-economy-to-face-pretty-limited-impact-from-israel-iran-airstrikes-with-only-a-tiny-bit-recession-risk-say-economists">are not expected</a> to significantly impact the U.S. economy, according to leading economists who stated that the U.S. economy&#8217;s outlook appears relatively stable despite potential risks.
However, the U.S.&#8217;s aggressive actions against Iran, a significant oil producer, have heightened regional tensions. This conflict, initially sparked by Israel&#8217;s extensive airstrikes, has thrust the global energy trade into the limelight. Energy markets braced for <a href="https://www.benzinga.com/markets/commodities/25/06/46046982/oil-prices-could-surge-by-10-as-us-drops-bunker-buster-bombs-on-iran-but-may-not-last-says-analyst-freight-disruptions-will-be-the-story-to-watch">potential disruptions</a> and a further surge in oil prices.
The stock market rallied on Monday following a performative retaliation by Iran, despite warnings of potential risks. The retaliation led to a 7% drop in oil prices and a ceasefire announced by President Donald Trump. However, Israel has accused Iran of violating the ceasefire, raising concerns about the future.
S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.96% while NASDAQ composite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) climbed 0.94% on Monday, according to data from <a href="http://pro.benzinga.com">Benzinga Pro.</a> 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/market-summary/25/06/46069852/global-markets-rally-oil-plunges-on-ceasefire-optimism">Global Markets Rally, Oil Plunges On Ceasefire Optimism</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market Rally Deceptive? Analysts Flag 3 Major Headwinds Investors Must Watch Now: 'Plenty Of Risk...'

LSPD

Lightspeed Partners With Whoosh For Scheduling, Payments And Memberships

Solésence, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLSN#NASDAQ">SLSN</a>), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it will be added as a member of the broad-market Russell 3000&#xAE; and small-cap Russell 2000&#xAE; Indexes, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution.
The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000&#xAE; Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000&#xAE; Index or small-cap Russell 2000&#xAE; Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

SLSN

Solésence To Join Russell 3000 And Russell 2000 Indexes, Effective June 30, 2025

The academic health system will soon handle personalized requests — like prescription refills and appointment scheduling — autonomously with Agentforce for Health to boost efficiency and deliver more responsive, patient-centered care
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.salesforce.com%2F&amp;esheet=54281124&amp;newsitemid=20250624764895&amp;lan=en-US&amp;anchor=Salesforce&amp;index=1&amp;md5=d24c22c24e125e1c90b8dcc00e46af97">Salesforce</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), the world's #1 AI CRM, today announced that UChicago Medicine is implementing <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.salesforce.com%2Fhealthcare-life-sciences%2Fhealthcare-artificial-intelligence%2F&amp;esheet=54281124&amp;newsitemid=20250624764895&amp;lan=en-US&amp;anchor=Agentforce+for+Health&amp;index=2&amp;md5=dbf6844440c1a9b1564b6a022a110810">Agentforce for Health</a> to enhance the patient experience. <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.salesforce.com%2Fagentforce%2F&amp;esheet=54281124&amp;newsitemid=20250624764895&amp;lan=en-US&amp;anchor=Agentforce&amp;index=3&amp;md5=7633e72f16ec585fa5295b3e64dc0d0a">Agentforce</a>, Salesforce's digital labor platform, is being integrated into the academic health system's non-clinical, operational workflows to provide patients with 24/7 access to tailored, self-service information and support.
UChicago Medicine identified opportunities to improve the efficiency of non-clinical support provided to patients, particularly for routine inquiries received outside of regular business hours. The addition of agentic, AI-powered tools is intended to alleviate pressure on staff by assisting with high-volume, non-urgent tasks and providing patients with timely responses to frequently asked questions.
With the integration of Agentforce and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.salesforce.com%2Fhealthcare-life-sciences%2Fhealth-cloud%2F&amp;esheet=54281124&amp;newsitemid=20250624764895&amp;lan=en-US&amp;anchor=Health+Cloud&amp;index=4&amp;md5=b5a4a4b9236947d68b773111f513bdef">Health Cloud</a>, digital, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.salesforce.com%2Fagentforce%2Fai-agents%2F&amp;esheet=54281124&amp;newsitemid=20250624764895&amp;lan=en-US&amp;anchor=AI&amp;index=5&amp;md5=9ba6c938e9071cb76309df9161b028f7">AI</a><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.salesforce.com%2Fagentforce%2Fai-agents%2F&amp;esheet=54281124&amp;newsitemid=20250624764895&amp;lan=en-US&amp;anchor=-powered&amp;index=6&amp;md5=5cffa1d3ea96442e6e9030bc33087c36">-powered</a><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.salesforce.com%2Fagentforce%2Fai-agents%2F&amp;esheet=54281124&amp;newsitemid=20250624764895&amp;lan=en-US&amp;anchor=agents&amp;index=7&amp;md5=5bd5635d6cad436c6b1728fe5f05678e"> agents</a> will help UChicago Medicine patients with a variety of information, from finding specialty care at convenient locations to answers about parking or directions.

Salesforce's Agentforce AI Platform To Power 24/7 Personalized Support At UChicago Medicine, Automating Prescription Refills, Appointment Scheduling, And Non-Clinical Tasks To Boost Efficiency And Enhance Patient Experience

Agentforce will enhance field operations and redefine the standard for customer engagement at PepsiCo
PURCHASE, N.Y. and SAN FRANCISCO, June 24, 2025 /PRNewswire/ --&nbsp;PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) today announced plans to deploy <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455395-1&amp;h=3752747609&amp;u=https%3A%2F%2Fwww.salesforce.com%2Fagentforce%2F&amp;a=Agentforce">Agentforce</a> — the digital labor platform from Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) for bringing trusted, autonomous AI agents into the flow of work. Through this expanded collaboration with Salesforce, the world's #1 AI CRM, PepsiCo will leverage AI agents to manage key functions, enhancing customer support and operational efficiency, while empowering sales teams to focus on strategic growth and deeper engagement with retailers. PepsiCo is one of the first major food and beverage companies to deploy Agentforce at scale, marking an important step in PepsiCo's AI roadmap.

PepsiCo Plans To Deploy Agentforce, Digital Labor Platform, From Salesforce For Bringing Autonomous AI Agents Into Flow Of Work

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~
~ Grant Funds from NIDA Accelerating Clinical Development Program ~
SAN DIEGO, CALIFORNIA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 24, 2025 / <a href="https://pr.report/brj7">Ensysce Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has fully enrolled Part 2 of the critical three-part PF614-MPAR-102 clinical study to study the effect of food on the MPAR technology.
PF614-MPAR has earned the FDA's prestigious Breakthrough Therapy designation and is uniquely engineered using Ensysce's proprietary TAAP&#x2122; (Trypsin-Activated Abuse Protection) and MPAR&#xAE; (Multi-Pill Abuse Resistance) technologies. These platforms enable PF614-MPAR to maintain therapeutic efficacy while delivering built-in overdose protection when doses exceed prescribed amounts, whether accidentally or intentionally.
A three-year grant from the National Institute on Drug Abuse (NIDA), with second year funding <a href="https://pr.report/brj8">recently announced</a>1, continues to support this program through May 2027. This support will accelerate the clinical development of PF614-MPAR and could help launch a new era in pain relief with overdose protection.

ENSC

Ensysce Biosciences Says It Fully Enrolled Part 2 Of Critical Three-Part PF614-MPAR-102 Clinical Study To Study Effect Of Food On MPAR Technology

Steve Eisman, the investor widely known for his role in shorting the subprime mortgage market before the 2008 financial crisis, says the U.S. banking landscape is increasingly consolidating into the hands of a <a href="https://www.benzinga.com/markets/cryptocurrency/25/06/45998961/ethereum-l2-chosen-for-jpmorgans-new-step-in-public-blockchain-space">few large banks</a>.
What Happened: Speaking on a financial podcast on Monday, Eisman <a href="https://www.youtube.com/watch?v=LvgCvJvAooE">highlighted</a> the growing concentration of deposits among major institutions like JPMorgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), which he said are steadily dominating the American banking sector.
Eisman noted that JPMorgan's share of U.S. deposits has risen from 7% in 2007 to nearly 14% today. 
"There are a couple of reasons for that," Eisman said. 
He pointed to the high costs of regulation and rapidly increasing technology expenses as key drivers that favor large banks. 
According to Eisman, these factors make it difficult for smaller and mid-sized banks to compete.
"If we do nothing, and we keep the current policies, and there's no M&amp;A wave, what's going to happen is JPMorgan, Wells Fargo, and a handful of others will continue to take market share," Eisman said. 
He explained that, under this scenario, smaller regional banks could gradually lose competitiveness, leaving a system dominated by a few megabanks and some small community banks.
"I would like more [banks], I don't want to be Canada, where it's basically a cartel," Eisman said, referring to Canada's highly concentrated banking system. 
He stressed that the U.S. should encourage mergers among regional banks like Comerica and U.S. Bank to ensure they can afford the scale and technology necessary to remain viable.
Eisman emphasized that large banks' ability to absorb compliance and technology costs gives them a structural advantage. Without regional consolidation, Eisman said, "the other regional banks are going to wither on the vine."
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46055372/new-crypto-fund-targets-early-builders-is-this-where-the-next-blockchain-unicorn-starts">New Crypto Fund Targets Early Builders: Is This Where The Next Blockchain Unicorn Starts?</a>
Why It Matters: On the broader financial sector, Eisman expressed positive views on large-cap banks like JPMorgan, Goldman Sachs, and Morgan Stanley in the absence of a trade war.
He said these firms are well-positioned to benefit from deregulation, a recovery in IPO activity, and increased M&amp;A transactions.
Eisman advised focusing on firms like Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) within the payments sector and said he prefers to avoid other payment companies, which he described as "all going after each other's space."
On smaller banks, Eisman said he currently does not own any regional bank stocks but suggested there could be an opportunity if policy shifts enable consolidation.
Eisman's commentary also touched on the historical trajectory of the U.S. financial system post-crisis. 
He explained that after the passage of Dodd-Frank, significant deleveraging took place across major banks.
He pointed out that Citigroup's leverage ratio dropped from 35:1 to 10:1 between 2011 and 2016.
"Your return on equity is going down" when leverage declines to that extent, Eisman said, underscoring why financial stocks have not delivered sustained outperformance in the post-crisis era.
Eisman stressed that structural changes, rather than isolated stock-specific events, are driving the industry's evolution. 
He noted that if consolidation among mid-sized banks does not happen, large banks are likely to continue increasing their dominance, reshaping the competitive dynamics of U.S. banking.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46053180/sequans-takes-a-page-from-microstrategy-is-bitcoin-the-new-corporate-treasury-play">Sequans Takes A Page From MicroStrategy: Is Bitcoin The New Corporate Treasury Play?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

'Big Short' Investor Eisman Warns JPMorgan, Wells Fargo Domination Squeezes Regional Banks

<ul>
<li>First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatments</li>
<li>Partnership aims to improve survival and quality of life for pediatric HLHS patients by developing new tools that can identify which children will potentially benefit most from surgery, transplantation, or novel therapies</li>
<li>Leveraging Novoheart's proprietary mini-Heart Platform, this partnership aligns with emerging FDA guidelines supporting human-relevant, animal-free drug development &nbsp;</li>
</ul>
BOSTON and SAN DIEGO and ROCHESTER, Minn., June 24, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, and Novoheart, its wholly owned pre-clinical subsidiary pioneering human-based cardiac tissue engineering for disease modelling and drug screening, today announced a groundbreaking collaboration with physician-scientists at the University of California San Diego School of Medicine and Mayo Clinic. The goal of the partnership is to develop the first human mini-heart models of hypoplastic left heart syndrome (HLHS) using stem cells from real patients and improve the understanding of this disease with the goal of developing more personalized treatment strategies for children born with this devastating condition.

KVAC

Medera And Novoheart Collaborate With Physician-Scientists At University Of California San Diego School Of Medicine And Mayo Clinic To Develop Mini-Heart Models Aimed At Transforming Treatment For HLHS

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval
Isaralgagene civaparvovec showed a favorable safety and tolerability profile

SGMO

Sangamo Therapeutics Announces Topline Results From Registrational Phase 1/2 STAAR Of ST-920 In Fabry Disease; Intends To Submit Biologics License Application In 2026

Guggenheim analyst Seamus Fernandez initiates coverage on Amylyx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) with a Buy rating and announces Price Target of $17.

Initiation

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Guggenheim Initiates Coverage On Amylyx Pharmaceuticals with Buy Rating, Announces Price Target of $17

<h3>Gainers</h3>
<ul>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares moved upwards by 9.0% to $0.58 during Tuesday's pre-market session. The market value of their outstanding shares is at $38.1 million. </li>
<li>Cenntro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENN#NASDAQ">CENN</a>) stock increased by 8.74% to $0.87. The market value of their outstanding shares is at $24.5 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares increased by 7.9% to $2.73. The company's market cap stands at $6.3 million. </li>
<li>Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) shares rose 7.2% to $12.2. The company's market cap stands at $140.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock fell 10.5% to $0.31 during Tuesday's pre-market session. The market value of their outstanding shares is at $12.2 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares declined by 10.3% to $0.1. The market value of their outstanding shares is at $5.5 million. </li>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) stock declined by 8.54% to $1.66. The market value of their outstanding shares is at $4.3 million. </li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) stock decreased by 8.01% to $1.15. The company's market cap stands at $31.5 million. </li>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares declined by 7.91% to $1.63. The market value of their outstanding shares is at $31.5 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock decreased by 7.47% to $0.92. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CENN

ECDA

LGCY

NTCL

RIME

XELB

ZCMD

10 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock moved upwards by 157.1% to $28.0 during Tuesday's pre-market session. The company's market cap stands at $181.7 million. </li>
<li>Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) stock increased by 14.1% to $2.75. The market value of their outstanding shares is at $245.0 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) stock rose 12.16% to $3.78. The company's market cap stands at $5.3 million. </li>
<li>Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) stock rose 11.7% to $11.74. The company's market cap stands at $62.9 million. </li>
<li>Rezolve AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) stock rose 10.78% to $2.26. The market value of their outstanding shares is at $497.0 million. </li>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) shares rose 10.34% to $1.28. The market value of their outstanding shares is at $17.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares fell 16.8% to $1.83 during Tuesday's pre-market session. The company's market cap stands at $79.3 million. </li>
<li>SmartKem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>) shares decreased by 11.49% to $0.82. The market value of their outstanding shares is at $4.0 million. </li>
<li>WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) stock decreased by 10.38% to $0.95. The market value of their outstanding shares is at $111.3 million. </li>
<li>Rail Vision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSN#NASDAQ">RVSN</a>) shares decreased by 9.84% to $0.28. The market value of their outstanding shares is at $6.2 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares decreased by 5.0% to $0.33. The market value of their outstanding shares is at $9.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BZAI

CMBM

GREE

MAPS

OBLG

RVSN

RZLV

SMTK

XTKG

11 Information Technology Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock rose 172.2% to $25.97 during Tuesday's pre-market session. The company's market cap stands at $118.3 million. </li>
<li>InMed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) stock moved upwards by 88.53% to $4.62. The company's market cap stands at $2.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock increased by 53.21% to $0.84. The market value of their outstanding shares is at $10.5 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 47.43% to $1.05. The market value of their outstanding shares is at $11.5 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) stock rose 37.18% to $20.99. The market value of their outstanding shares is at $298.3 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 24.68% to $0.23. The company's market cap stands at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 30.4% to $1.12 during Tuesday's pre-market session. The company's market cap stands at $19.4 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares fell 19.35% to $0.4. The market value of their outstanding shares is at $8.0 million. </li>
<li>ViewBix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIX#NASDAQ">VBIX</a>) shares declined by 14.48% to $3.31. The company's market cap stands at $25.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares declined by 13.34% to $1.43. The market value of their outstanding shares is at $5.3 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock fell 11.39% to $1.09. The company's market cap stands at $19.0 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock declined by 11.05% to $0.21. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

CBIO

DHAI

IBIO

INDP

NKTR

PSTV

SNGX

TRIB

VBIX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Press Releases

NRG Energy, GE Vernova and Kiewit Accelerating New Generation Capacity to Support Demand Growth

PyroGenesis and GE Vernova Sign Memorandum of Understanding (MOU)

Homer City Redevelopment and Kiewit Announce Country's Largest Natural Gas-Powered Data Center Campus to Support AI and HPC Demand

GE Vernova Declares Second Quarter 2025 Dividend

Ericsson, GE Vernova, and Nokia Offering High-Value Incentives to Utilities via AnterixAccelerator™ to Enhance 900 MHz Spectrum Offering

Homer City Redevelopment Appoints Corey Hessen as CEO

NYSE Content Advisory: Pre-Market update + Tesla to report earnings

Commodities

Contracts

Duke Energy and GE Vernova announce significant arrangement for gas turbines and associated equipment

Comments

GE Vernova

Noticias

Últimas noticias sobre GE Vernova (NYSE:GEV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL